China Medical System Holdings Limited (FRA:2M7C)

Market Cap	3.62B
Revenue (ttm)	988.38M
Net Income (ttm)	214.35M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	16.87
Forward PE	18.31
Dividend	0.03 (2.31%)
Ex-Dividend Date	Apr 28, 2025

Volume	530
Average Volume	451
Open	1.470
Previous Close	1.460
Day's Range	1.470 - 1.470
52-Week Range	0.740 - 1.490
Beta	n/a
RSI	50.74
Earnings Date	Aug 18, 2025

About FRA:2M7C

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 6,141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2M7C

Financial Performance

In 2024, FRA:2M7C's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.

Financial numbers in CNY